Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity

20 Apr 2022

On the way to seeking approval for istaroxime in acute heart failure, Windtree became convinced that early cardiogenic shock could be a good get-to-market strategy for its blood pressure-improving drug.

Heart failure care — Windtree hopes its novel drug will provide innovation in cardiogenic shock care • Source: Alamy

Windtree Therapeutics, Inc. hopes eventually to bring its first-in-class SERCA 2a activator istaroxime to market for treatment of acute heart failure, but along the way to getting potentially approvable data for that indication it determined that another cardiovascular setting, early cardiogenic shock (ECS), could offer a simpler, less expensive means for getting the drug on the market.

The Warrington, PA-based company unveiled top-line data from the Phase II SEISMiC trial of istaroxime in ECS on 20 April,...